These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 2203517)

  • 21. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails.
    Kassouf W; Tanguay S; Aprikian AG
    J Urol; 2003 May; 169(5):1742-4. PubMed ID: 12686822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nilutamide response after flutamide failure in post-orchiectomy progressive prostate cancer.
    Eastham JA; Sartor O
    J Urol; 1998 Mar; 159(3):990. PubMed ID: 9474206
    [No Abstract]   [Full Text] [Related]  

  • 23. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide).
    Kuhn JM; Billebaud T; Navratil H; Moulonguet A; Fiet J; Grise P; Louis JF; Costa P; Husson JM; Dahan R
    N Engl J Med; 1989 Aug; 321(7):413-8. PubMed ID: 2503723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of androgen deprivation therapy on local symptoms and tumour progression in men with metastatic carcinoma of the prostate.
    Smith JA; Janknegt RA; Abbou CC; de Gery A
    Eur Urol; 1997; 31 Suppl 3():25-9. PubMed ID: 9101212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. French multicentre trial comparing Casodex (ICI 176,334) monotherapy with castration plus nilutamide in metastatic prostate cancer: a preliminary report.
    Chatelain C; Rousseau V; Cosaert J
    Eur Urol; 1994; 26 Suppl 1():10-4. PubMed ID: 7737255
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy.
    Madan RA; Gulley JL; Schlom J; Steinberg SM; Liewehr DJ; Dahut WL; Arlen PM
    Clin Cancer Res; 2008 Jul; 14(14):4526-31. PubMed ID: 18628467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anandron (RU 23908) associated to surgical castration in previously untreated stage D prostate cancer: a multicenter comparative study of two doses of the drug and of a placebo.
    Brisset JM; Boccon-Gibod L; Botto H; Camey M; Cariou G; Duclos JM; Duval F; Gontiès D; Jorest R; Lamy L
    Prog Clin Biol Res; 1987; 243A():411-22. PubMed ID: 3309973
    [No Abstract]   [Full Text] [Related]  

  • 28. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group.
    Lancet; 2000 Apr; 355(9214):1491-8. PubMed ID: 10801170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiandrogen withdrawal syndrome with nilutamide.
    Huan SD; Gerridzen RG; Yau JC; Stewart DJ
    Urology; 1997 Apr; 49(4):632-4. PubMed ID: 9111642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Total androgen blockade vs orchiectomy in stage D2 prostate cancer.
    Béland G; Elhilali M; Fradet Y; Laroche B; Ramsey EW; Venner PM; Tewari HD
    Prog Clin Biol Res; 1987; 243A():391-400. PubMed ID: 3116550
    [No Abstract]   [Full Text] [Related]  

  • 31. A comparison of the treatment of metastatic prostate cancer by testicular ablation or total androgen blockade. The Canadian Anandron Study Group.
    Cancer Treat Res; 1992; 59():29-40. PubMed ID: 1347692
    [No Abstract]   [Full Text] [Related]  

  • 32. A randomized double-blind study evaluating Anandron associated with orchiectomy in stage D prostate cancer.
    Namer M; Toubol J; Caty A; Couette JE; Douchez J; Kerbrat P; Droz JP
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):909-15. PubMed ID: 2285605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
    Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
    Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
    Eisenberger MA; Blumenstein BA; Crawford ED; Miller G; McLeod DG; Loehrer PJ; Wilding G; Sears K; Culkin DJ; Thompson IM; Bueschen AJ; Lowe BA
    N Engl J Med; 1998 Oct; 339(15):1036-42. PubMed ID: 9761805
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First-line treatment of metastatic prostate cancer. Androgen suppression for symptomatic disease.
    Prescrire Int; 2013 Feb; 22(135):48-51. PubMed ID: 23444510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Fatal fulminant hepatitis induced by nilutamide (Anandron)].
    Pescatore P; Hammel P; Durand F; Bertheau P; Bernuau J; Huc D; Gerbal JL; Degott C; Benhamou JP
    Gastroenterol Clin Biol; 1993; 17(6-7):499-501. PubMed ID: 8243938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic factor analysis in patients with advanced prostate cancer treated by castration plus anandron or placebo: a final update.
    de Reijke T; Derobert E;
    Eur Urol; 2002 Aug; 42(2):139-46. PubMed ID: 12160584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.
    Harris MG; Coleman SG; Faulds D; Chrisp P
    Drugs Aging; 1993; 3(1):9-25. PubMed ID: 8453188
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of the pure non-steroidal antiandrogen nilutamide in prostatic cancer. Italian Prostatic Cancer Project (PONCAP).
    Decensi A; Guarneri D; Paoletti MC; Lalanne JM; Merlo F; Boccardo F
    Eur J Cancer; 1991; 27(9):1100-4. PubMed ID: 1835617
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Combined anti-androgen treatment in adenocarcinoma of the prostate: first use of a new therapeutically efficacious principle in hormone-dependent cancer].
    Labrie F; Dupont A; Bélanger A; Lacourcière Y; Monfette JE; Monfette G
    Ann Urol (Paris); 1986; 20(2):98-106. PubMed ID: 2940959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.